Senate Bill Would Make Biosimilars Automatically Interchangeable, Cutting Drug Switching Red Tape
A senate committee must act next: committee consideration.
No action since June 2025
This bill’s path across every version that has carried it.
How this policy affects specific groups of people
Read twice and referred to the Committee on Health, Education, Labor, and Pensions.
Sent to a congressional committee for expert review. The committee decides whether this bill moves forward.
Introduced in Senate
The bill was officially filed and given a number. It now enters the legislative queue.
Senate HELP Committee Chair Bill Cassidy released a report proposing reforms to the FDA review process, including codifying the agency's stance that all approved biosimilars should be considered interchangeable. The report aligns with the goals of the Biosimilar Red Tape Elimination Act.
This report examines the potential risks of the Biosimilar Red Tape Elimination Act, noting that classifying all biosimilars as interchangeable without switching studies could weaken FDA standards and undermine physician confidence in pharmacy-level substitutions.
Senator Mike Lee reintroduced the Biosimilar Red Tape Elimination Act to end switching study requirements for companies seeking interchangeability designations. The bill would amend federal code to state that all biosimilars are deemed interchangeable upon initial FDA approval.
No votes recorded for this bill yet.
Document Type
Congressional Bill
Official Title
Biosimilar Red Tape Elimination Act
Analysis generated by AI. Always verify with official sources.